Wong WL, Su X, Li X et al (2014) Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2:e106–e116

Article  PubMed  Google Scholar 

Mitchell P, Liew G, Gopinath B, Wong TY (2018) Age-related macular degeneration. Lancet 392:1147–1159

Article  PubMed  Google Scholar 

Wormald R, Evans J, Smeeth L, Henshaw K (2007) Photodynamic therapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev CD002030.

Brown DM, Kaiser PK, Michels M et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432–1444

Article  CAS  PubMed  Google Scholar 

Rofagha S, Bhisitkul RB, Boyer DS et al (2013) Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 120:2292–2299

Article  PubMed  Google Scholar 

Traine PG, Pfister IB, Zandi S et al (2019) Long-term outcome of intravitreal aflibercept treatment for neovascular age-related macular degeneration using a “treat-and-extend” regimen. Ophthalmol Retina 3:393–399

Article  PubMed  Google Scholar 

Nguyen QD, Das A, Do DV et al (2020) Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration. Ophthalmology 127:963–976

Article  PubMed  Google Scholar 

Dugel PU, Singh RP, Koh A et al (2021) HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 128:89–99

Article  PubMed  Google Scholar 

Matsumoto H, Hoshino J, Mukai R et al (2021) Short-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy. Sci Rep 11:6759

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haensli C, Pfister IB, Garweg JG (2021) Switching to brolucizumab in neovascular age-related macular degeneration incompletely responsive to ranibizumab or aflibercept: real-life 6 month outcomes. J Clin Med 10

Monés J, Srivastava SK, Jaffe GJ et al (2021) Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER. Ophthalmology 128:1050–1059

Article  PubMed  Google Scholar 

Haug SJ, Hien DL, Uludag G et al (2020) Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration. Am J Ophthalmol Case Rep 18:100680

Article  PubMed  PubMed Central  Google Scholar 

Jain A, Chea S, Matsumiya W et al (2020) Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations. Am J Ophthalmol Case Rep 18:100687

Article  PubMed  PubMed Central  Google Scholar 

Khoramnia R, Figueroa MS, Hattenbach L-O et al (2022) Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular AMD. Graefes Arch Clin Exp Ophthalmol 260:1843–1856

Article  CAS  PubMed  Google Scholar 

Baumal CR, Bodaghi B, Singer M et al (2021) Expert opinion on management of intraocular inflammation, retinal vasculitis, and vascular occlusion after Brolucizumab treatment. Ophthalmol Retina 5:519–527

Article  PubMed  Google Scholar 

Yannuzzi LA, Wong DW, Sforzolini BS et al (1999) Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration. Arch Ophthalmol 117:1503–1510

Article  CAS  PubMed  Google Scholar 

Maruko I, Iida T, Saito M et al (2007) Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 144:15–22

Article  PubMed  Google Scholar 

Singerman LJ, Brucker AJ, Jampol LM et al (2005) Neovascular age-related macular degeneration: roundtable. Retina 25:S1–S22

Article  PubMed  Google Scholar 

Barthelmes D, Nguyen V, Daien V et al (2018) Two year outcomes of “treat and extend” intravitreal therapy using Aflibercept preferentially for Neovascular age-related macular degeneration. Retina 38:20–28

Article  CAS  PubMed  Google Scholar 

Berg K, Pedersen TR, Sandvik L, Bragadóttir R (2015) Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology 122:146–152

Article  PubMed  Google Scholar 

Cohen SY, Dubois L, Tadayoni R et al (2009) Results of one-year’s treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. Am J Ophthalmol 148:409–413

Article  CAS  PubMed  Google Scholar 

Guex-Crosier Y, Pittet N, Herbort CP (1995) Sensitivity of laser flare photometry to monitor inflammation in uveitis of the posterior segment. Ophthalmology 102:613–621

Article  CAS  PubMed  Google Scholar 

Herbort CP, Guex-Crosier Y, de Ancos E, Pittet N (1997) Use of laser flare photometry to assess and monitor inflammation in uveitis. Ophthalmology 104:64–71

Article  CAS  PubMed  Google Scholar 

Tadayoni R, Sararols L, Weissgerber G et al (2021) Brolucizumab: a newly developed anti-VEGF molecule for the treatment of neovascular age-related macular degeneration. Ophthalmologica 244:93–101

Article  CAS  PubMed  Google Scholar 

Mukai R, Matsumoto H, Akiyama H (2021) Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration. PLoS ONE 16:e0259879

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maruko I, Okada AA, Iida T et al (2021) Brolucizumab-related intraocular inflammation in Japanese patients with age-related macular degeneration: a short-term multicenter study. Graefes Arch Clin Exp Ophthalmol 259:2857–2859

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rossi S, D’Amico M, Capuano A et al (2006) Hyperglycemia in streptozotocin-induced diabetes leads to persistent inflammation and tissue damage following uveitis due to reduced levels of ciliary body heme oxygenase-1. Mediators Inflamm 2006:60285

Article  PubMed  PubMed Central  Google Scholar 

Shimura M, Yasuda K (2010) Macular ischaemia after intravitreal bevacizumab injection in patients with central retinal vein occlusion and a history of diabetes and vascular disease. Br J Ophthalmol 94:381–383

Article  PubMed  Google Scholar 

Baumal CR, Spaide RF, Vajzovic L et al (2020) Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab. Ophthalmology 127:1345–1359

Article  PubMed  Google Scholar 

Witkin AJ, Hahn P, Murray TG et al (2020) Occlusive retinal vasculitis following intravitreal brolucizumab. J Vitreoretin Dis 4:269–279

Article  PubMed  PubMed Central  Google Scholar 

Subhi Y, Krogh Nielsen M, Molbech CR et al (2019) Association of CD11b+ monocytes and anti-vascular endothelial growth factor injections in treatment of neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. JAMA Ophthalmol 137:515–522

Article  PubMed  PubMed Central  Google Scholar 

Tugal-Tutkun I, Herbort CP (2010) Laser flare photometry: a noninvasive, objective, and quantitative method to measure intraocular inflammation. Int Ophthalmol 30:453–464

Article  PubMed  Google Scholar 

Agrawal R, Keane PA, Singh J et al (2016) Comparative analysis of anterior chamber flare grading between clinicians with different levels of experience and semi-automated laser flare photometry. Ocul Immunol Inflamm 24:184–193

PubMed  Google Scholar 

Tugal-Tutkun I, Cingü K, Kir N et al (2008) Use of laser flare-cell photometry to quantify intraocular inflammation in patients with Behçet uveitis. Graefes Arch Clin Exp Ophthalmol 246:1169–1177

Article  PubMed  Google Scholar 

Jiang S, Liu X, Luo L et al (2011) Serum levels of Th17-related cytokines in Behcet disease patients after cataract surgery. Mol Vis 17:1425–1430

CAS  PubMed  PubMed Central  Google Scholar 

Funatsu H, Yamashita H, Noma H et al (2002) Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol 133:70–77

Article  CAS  PubMed  Google Scholar 

Noma H, Mimura T, Shimada K (2014) Role of inflammation in previously untreated macular edema with branch retinal vein occlusion. BMC Ophthalmol 14:67

Article  PubMed  PubMed Central  Google Scholar 

Noma H, Mimura T, Tatsugawa M, Shimada K (2013) Aqueous flare and inflammatory factors in macular edema with central retinal vein occlusion: a case series. BMC Ophthalmol 13:78

Article  PubMed  PubMed Central  Google Scholar 

Saito M, Kobori H, Nozuki N et al (2022) A case of intraocular inflammation after intravitreal brolucizumab injection monitored by laser flare-cell photometer. Am J Ophthalmol Case Rep 28:101727

Article  PubMed  PubMed Central  Google Scholar 

Taipale C, Lindholm J-M, Tuuminen R (2018) Aqueous flare as a marker of retinal disease activity after anti-VEGF injections. Acta Ophthalmol 96:e1043–e1044